Not Yet RecruitingPhase 4

A Randomized Feasibility Trial Comparing Drospirenone and Norethindrone for Postpartum Hypertension Management in Preeclampsia

United States50 participantsStarted 2026-07

Plain-language summary

This is an open-label, randomized feasibility trial in which patients admitted to Oregon Health \& Science University (OHSU) after a pregnancy complicated by preeclampsia who are considering a progestin-only pill contraception postpartum will be randomized to norethindrone or drospirenone for 6 weeks following hospital discharge.

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Admission to Oregon Health \& Science University following a birth (during the same admission) * A diagnosis of preeclampsia or chronic hypertension with superimposed preeclampsia (with or without severe features) * Considering use of a progestin-only pill for postpartum contraception Exclusion Criteria: * Planned use of a contraceptive method other than a progestin-only pill * Contraindications to drospirenone or norethindrone * Inability to monitor blood pressure at home after discharge * Inability to complete follow-up surveys by email in English

What they're measuring

Blood Pressure

Timeframe: Measured weekly for the 6 weeks following delivery.

Trial details

NCT IDNCT07293728

SponsorOregon Health and Science University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-12

Contact for this trial

Women's Health Research Unit Department of OB/Gyn

503-494-3666 whru@ohsu.edu

View on ClinicalTrials.gov More Hypertension trials